{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T11:47:42Z","timestamp":1759664862287,"version":"3.38.0"},"reference-count":30,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2011,6,29]],"date-time":"2011-06-29T00:00:00Z","timestamp":1309305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2011,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Intravesical onabotulinumtoxinA (BoNT\u2010A) injection is a promising treatment for refractory detrusor overactivity (DO). This study investigated the long\u2010term success rate of BoNT\u2010A injection for patients with idiopathic DO and its association with reduction of urgency severity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study was a retrospective analysis of 174 patients with idiopathic DO who received first\u2010time 100\u2009U BoNT\u2010A injections. The patients were collected from several previous clinical trials. The therapeutic effects were classified as significant sensory effects with urgency severity score reductions of \u22652 and\/or significant motor effects with cystometric bladder capacity increases of \u226525%. The treatment results based on patients' perceptions of bladder conditions and long\u2010term success rates were analyzed among the different therapeutic\u2010effect subgroups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A successful outcome was reported by 138 (79.3%) patients at 3 months. Seventy\u2010seven (44.3%) patients had both sensory and motor effects, 5 (2.9%) had sensory effects alone, 83 (47.7%) had motor effects alone, and 9 (5.2%) had no sensory or motor effect. All 82 patients with sensory with\/without motor effects reported a successful result. In contrast, only 50 (60.2%) patients with motor effects alone reported success at 3 months. Increased cystometric bladder capacity and postvoid residual and decreased voiding efficiency were noted in patients with motor with\/without sensory effects. The therapeutic results lasted significantly longer in patients with sensory with\/without motor effects than those with motor effects alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Improvement of urgency severity is significantly associated with a higher success rate at 3 months and longer therapeutic duration after intravesical BoNT\u2010A injection for IDO. Neurourol. Urodynam. Neurourol. Urodynam. 30: 1497\u20131502, 2011. \u00a9 2011 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.21132","type":"journal-article","created":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T15:19:58Z","timestamp":1309447198000},"page":"1497-1502","source":"Crossref","is-referenced-by-count":26,"title":["Reduction of urgency severity is associated with long\u2010term therapeutic effect after intravesical onabotulinumtoxina injection for idiopathic detrusor overactivity"],"prefix":"10.1002","volume":"30","author":[{"given":"Hann\u2010Chorng","family":"Kuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,6,29]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10052"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00492-6"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02190.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000169481.42259.54"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3565(25)31908-7","article-title":"Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction","volume":"212","author":"Simpson LL","year":"1980","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2003.12.007"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.01.130"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.03.028"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.09.009"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000169480.43557.31"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05725.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20105"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2004.11.052"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.02.002"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.05.054"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.05.136"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.21054"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000165461.38088.7b"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.01.007"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.43.7s.3.x"},{"key":"e_1_2_6_22_2","first-page":"414","article-title":"Botulinum toxin type A (BTX\u2010A) reduces inflammatory pain in the rat formalin model","volume":"20","author":"Cui M","year":"2000","journal-title":"Cephalalgia"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.01.036"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.02.009"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.08.021"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(06)00590-8"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20611"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2005.01.017"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.02.037"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.04.037"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.05.007"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.21132","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.21132","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.21132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T21:04:48Z","timestamp":1741295088000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.21132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,29]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.1002\/nau.21132"],"URL":"https:\/\/doi.org\/10.1002\/nau.21132","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"type":"print","value":"0733-2467"},{"type":"electronic","value":"1520-6777"}],"subject":[],"published":{"date-parts":[[2011,6,29]]}}}